GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinopharm Group Co Ltd (OTCPK:SHTDF) » Definitions » EV-to-Revenue

SHTDF (Sinopharm Group Co) EV-to-Revenue : 0.21 (As of Apr. 26, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Sinopharm Group Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sinopharm Group Co's enterprise value is $16,645 Mil. Sinopharm Group Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $80,427 Mil. Therefore, Sinopharm Group Co's EV-to-Revenue for today is 0.21.

The historical rank and industry rank for Sinopharm Group Co's EV-to-Revenue or its related term are showing as below:

SHTDF' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.17   Med: 0.25   Max: 0.51
Current: 0.21

During the past 13 years, the highest EV-to-Revenue of Sinopharm Group Co was 0.51. The lowest was 0.17. And the median was 0.25.

SHTDF's EV-to-Revenue is ranked better than
79.09% of 110 companies
in the Medical Distribution industry
Industry Median: 0.655 vs SHTDF: 0.21

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-04-26), Sinopharm Group Co's stock price is $2.30. Sinopharm Group Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $25.77. Therefore, Sinopharm Group Co's PS Ratio for today is 0.09.


Sinopharm Group Co EV-to-Revenue Historical Data

The historical data trend for Sinopharm Group Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinopharm Group Co EV-to-Revenue Chart

Sinopharm Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.20 0.20 0.19 0.22

Sinopharm Group Co Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.59 0.19 - -

Competitive Comparison of Sinopharm Group Co's EV-to-Revenue

For the Medical Distribution subindustry, Sinopharm Group Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinopharm Group Co's EV-to-Revenue Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sinopharm Group Co's EV-to-Revenue falls into.


;
;

Sinopharm Group Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sinopharm Group Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=16645.080/80426.909
=0.21

Sinopharm Group Co's current Enterprise Value is $16,645 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Group Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $80,427 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co  (OTCPK:SHTDF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sinopharm Group Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=2.30/25.773
=0.09

Sinopharm Group Co's share price for today is $2.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was $25.77.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinopharm Group Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sinopharm Group Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinopharm Group Co Business Description

Traded in Other Exchanges
Address
No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.

Sinopharm Group Co Headlines

From GuruFocus

Matthews China Fund Comments on Sinopharm

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund 1st Quarter Commentary

By Holly LaFon Holly LaFon 05-19-2016

Matthews China Fund Comments on Sinopharm Group

By Vera Yuan Vera Yuan 10-20-2014

Matthews China Fund Q3 2014 Commentary

By Holly LaFon Holly LaFon 10-18-2014

Sinopharm Group Co Ltd's Dividend Analysis

By GuruFocus Research 06-17-2024

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 01-25-2021

Matthews China Fund Comments on Sinopharm

By Sydnee Gatewood Sydnee Gatewood 07-30-2020